Jul 29 2025
Healthcare
Recent Research
hVIVO, H1 trading statement
Jul 22 2025
hVIVO, Trading update
May 30 2025
Uniphar, AGM statement
May 8 2025
CVS Group, CMA working paper on remedies
May 1 2025
CVS Group, Disposal of crematoria division
Apr 24 2025
Meet your Healthcare Research team
Uniphar
H1 2025 trading statement drives further upgrades
Uniphar has issued a trading statement ahead of its H1 2025 results, which will be published on September 2nd. All divisions are performing strongly with c.8% organic gross profit growth....
CVS Group
FY2025 trading statement is in line with expectations
CVS has issued a trading statement for FY2025 to June 30th. Revenues are close to our forecast and were impacted by weak market conditions in the UK. EBITDA is in line with our...
hVIVO
H1 trading statement
hVIVO has issued a trading statement for H1, reiterating FY2025 revenue guidance and indicating a slight improvement in the outlook for EBITDA. The sector remains challenged due to...
hVIVO
Trading update
hVIVO has announced that it has received notification of a significant contract cancellation alongside a postponement and a cancellation of a smaller study. This is due to uncertainty in...
Uniphar
AGM statement
Uniphar will have its AGM later this morning. Ahead of that, the company has confirmed that its capex programmes remain on track, it has reiterated its medium-term EBITDA target,...
CVS Group
CMA working paper on remedies
The Competition and Markets Authority (CMA) has published its working paper on remedies, which primarily focuses on improving disclosure in the market. There is the potential for some...
CVS Group
Disposal of crematoria division
After receiving an attractive offer of 10x EV/EBITDA for its crematoria division, CVS has announced its disposal for £42.4m. The capital will be recycled into further acquisitions in...
hVIVO
FY2024 results
hVIVO has published its FY2024 results. It provided the key figures for 2024 and guidance on 2025 in its January trading statement. 2024 was a record year for the company in terms of...
Uniphar
Upgrading forecasts and revisiting the investment case
Following the recent share buyback, we are upgrading our Uniphar EPS forecasts by 3% in both 2025 and 2026. We upgraded by 2% in January. EPS could accelerate higher post completion...
CVS Group
Updating our forecasts and revisiting the investment case
We lower our EPS forecasts by 5-6% each year from higher depreciation and interest charges associated with investments. There are further risks to forecasts looking ahead. However,...
